232 related articles for article (PubMed ID: 36883121)
1. Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy.
Su T; Liu X; Lin S; Cheng F; Zhu G
Bioact Mater; 2023 Aug; 26():169-180. PubMed ID: 36883121
[TBL] [Abstract][Full Text] [Related]
2. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.
Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G
Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773
[TBL] [Abstract][Full Text] [Related]
3. Lymph node-targeting adjuvant/neoantigen-codelivering vaccines for combination glioblastoma radioimmunotherapy.
Su T; Zhou S; Yang S; Humble N; Zhang F; Yu G; Bos PD; Cheng F; Valerie K; Zhu G
Theranostics; 2023; 13(13):4304-4315. PubMed ID: 37649594
[TBL] [Abstract][Full Text] [Related]
4. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
[TBL] [Abstract][Full Text] [Related]
5. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
[TBL] [Abstract][Full Text] [Related]
6. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
7. TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.
Castro Eiro MD; Hioki K; Li L; Wilmsen MEP; Kiernan CH; Brouwers-Haspels I; van Meurs M; Zhao M; de Wit H; Grashof DGB; van de Werken HJG; Mueller YM; Schliehe C; Temizoz B; Kobiyama K; Ishii KJ; Katsikis PD
J Immunol; 2024 Feb; 212(3):455-465. PubMed ID: 38063488
[TBL] [Abstract][Full Text] [Related]
8. Programming peptide-oligonucleotide nano-assembly for engineering of neoantigen vaccine with potent immunogenicity.
Xiang Z; Lu J; Rao S; Fu C; Yao Y; Yi Y; Ming Y; Sun W; Guo W; Chen X
Theranostics; 2024; 14(6):2290-2303. PubMed ID: 38646651
[No Abstract] [Full Text] [Related]
9. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
10. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy.
Liang Z; Cui X; Yang L; Hu Q; Li D; Zhang X; Han L; Shi S; Shen Y; Zhao W; Ju Q; Deng X; Wu Y; Sheng W
Int J Pharm; 2021 Oct; 608():121091. PubMed ID: 34555477
[TBL] [Abstract][Full Text] [Related]
11. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
[TBL] [Abstract][Full Text] [Related]
12. A Universal Cyclodextrin-Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity.
Mao J; Jin Z; Rui X; Li L; Hou C; Leng X; Bi X; Chen Z; Chen Y; Wang J
Adv Healthc Mater; 2023 Oct; 12(27):e2301099. PubMed ID: 37602523
[TBL] [Abstract][Full Text] [Related]
13. Allomelanin-based biomimetic nanotherapeutics for orthotopic glioblastoma targeted photothermal immunotherapy.
Sun M; Li Y; Zhang W; Gu X; Wen R; Zhang K; Mao J; Huang C; Zhang X; Nie M; Zhang Z; Qi C; Cai K; Liu G
Acta Biomater; 2023 Aug; 166():552-566. PubMed ID: 37236575
[TBL] [Abstract][Full Text] [Related]
14. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
15. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
16. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
17. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
Nakagawa T; Tanino T; Onishi M; Tofukuji S; Kanazawa T; Ishioka Y; Itoh T; Kugimiya A; Katayama K; Yamamoto T; Nagira M; Ishii KJ
Front Immunol; 2021; 12():803090. PubMed ID: 35003132
[TBL] [Abstract][Full Text] [Related]
18. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
19. Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity.
Manna S; Maiti S; Shen J; Weiss A; Mulder E; Du W; Esser-Kahn AP
Biomaterials; 2023 May; 296():122062. PubMed ID: 36863071
[TBL] [Abstract][Full Text] [Related]
20. Vaccine-like nanomedicine for cancer immunotherapy.
Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]